ClinicalTrials.gg
TerminatedNCT05966454CASA RELAXUpdated Oct 27, 2026Results posted

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF

A Phase 4 interventional study of Multiple standard of care antibiotics for appendicitis, at physicians' discretion and Multiple standard of care antibiotics for appendicitis, at physicians' discretion in Appendicitis, sponsored by University of California, San Francisco. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Not feasible to complete trial due to low enrollment rate. Enrollment terminated and inadequately powered to achieve statistical significance on primary and secondary study outcomes.
Updated Oct 27, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Appendicitis with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Appendicitis · United States.

Enrollment
37th of 59
42 · median 98
Started
2023
with 5 others
Phase 4
10 of 78
2 open now
Registered
72nd of 78
by date

Among the 78 studies in Appendicitis with a site in United States, this one is the 37th largest by enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2023, is one of 10 in phase 4, and was the 72nd registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

6 of the 78 studies in Appendicitis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Appendicitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the safety, efficacy, and feasibility of short-course post-operative antibiotic treatment for simple and complicated appendicitis

Read the detailed description

This is a single center, randomized controlled trial to determine if decreasing the amount of antibiotics after appendicitis surgery can decrease the risk of adverse effects associated with antibiotics while at the same time ensuring participant safety.

03

Conditions studied

  • Appendicitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years

  • Age ≥ 18 years
  • Planned appendectomy (laparoscopic or open)
  • Working telephone number or reliable method to contact patient after hospital discharge

Exclusion criteria

Exclusion Criteria:

  • Unable to consent
  • Pregnant Women
  • Prisoners
  • as determined by clinical team, or patients actively receiving , chemotherapy, or immunosuppressing medications (for example tacrolimus), or patients with active hematologic affecting the immune system, leukopenia, or end-stage AIDS
  • Heart failure
  • Allergy to bupivacaine
  • Unlikely to comply with treatment or follow-up
  • Inpatient consultation for appendicitis
  • Clinically suspected of sepsis based on Sepsis-3 definition
  • Current use of antibiotics for other indications
  • Type 1 Diabetes or uncontrolled hyperglycemia
  • Surgeon preference
  • Patient preference
  • Research team unavailable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Restricted Post-Operative Antibiotics Group

    Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics. Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics.

    Drug: Multiple standard of care antibiotics for appendicitis, at physicians' discretion

  • Active comparator
    Liberal Post-Operative Antibiotics Group

    Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics.

    Drug: Multiple standard of care antibiotics for appendicitis, at physicians' discretion

Interventions

  • DrugMultiple standard of care antibiotics for appendicitis, at physicians' discretion

    Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.

  • DrugMultiple standard of care antibiotics for appendicitis, at physicians' discretion

    Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Infectious/Antibiotic Complication

    Infectious/antibiotic complication requiring antibiotic treatment only, Emergency Department visit, hospital readmission, percutaneous drainage, and operative intervention as assessed by treating physician.

    Time frame: Up to 30 days after appendicitis surgery

  2. Number of Participant Deaths

    Up to 30 days after appendicitis surgery

    Time frame: Up to 30 days after appendicitis surgery

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneRestricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics Group
Started2121
Completed2121
Not completed00

Outcome measures

PrimaryNumber of Participants With Infectious/Antibiotic Complication

Infectious/antibiotic complication requiring antibiotic treatment only, Emergency Department visit, hospital readmission, percutaneous drainage, and operative intervention as assessed by treating physician.

Time frame:
Up to 30 days after appendicitis surgery
Reported as:
Count of participants · Participants
Number of Participants With Infectious/Antibiotic Complication
ParticipantsRestricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics Group
Number of Participants With Infectious/Antibiotic Complication01
PrimaryNumber of Participant Deaths

Up to 30 days after appendicitis surgery

Time frame:
Up to 30 days after appendicitis surgery
Reported as:
Count of participants · Participants
Number of Participant Deaths
ParticipantsRestricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics Group
Number of Participant Deaths00

Adverse events

Collected over Up to 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Restricted Post-Operative Antibiotics Group0/21 (0%)0/21 (0%)0/21 (0%)
Liberal Post-Operative Antibiotics Group0/21 (0%)0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Restricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics GroupTotal
Mean34 ± 1329 ± 732 ± 11
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Restricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics GroupTotal
Male111526
Female9615
Transgender101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Restricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics GroupTotal
Asian213
African American101
Hispanic141933
Native Hawaiian or Other Pacific Islander101
White213
Unknown/Not Available101
Number of Participants who Received Antibiotics in the Emergency Department Prior to Operation
Number of Participants who Received Antibiotics in the Emergency Department Prior to Operation(Participants)Restricted Post-Operative Antibiotics GroupLiberal Post-Operative Antibiotics GroupTotal
Count of participants161430
08

Study locations

1 site
  • Zuckerberg San Francisco General Hospital
    San Francisco, California 94110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Patient data will be shared with Denver health and combined with data from other independent sites for final analysis

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2025, 25 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 28, 2023
StartActual
Jun 6, 2023
Primary completionActual
Jul 16, 2025
CompletionActual
Jul 16, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Enrollment
40→42
Oct 27, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedIncidenceNumber of Participants With Infectious/Antibiotic ComplicationsComplicationTime frame: Up to 30 days after appendicitis surgery
  • EditedNumber of participant deathsParticipant DeathsTime frame: Up to 30 days after appendicitis surgery
Oct 27, 2026
Documents
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Enrollment 40→42
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedIncidenceNumber of Participants With Infectious/Antibiotic ComplicationsComplicationTime frame: Up to 30 days after appendicitis surgery
    • EditedNumber of participant deathsParticipant DeathsTime frame: Up to 30 days after appendicitis surgery
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05966454
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Jun 6, 2023
Primary completion
Jul 16, 2025
Completion
Jul 16, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Lucy Kornblith, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion